The HABP4 Knockout HAP1 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout population of HAP1 cells, with targeted disruption of the HABP4 gene. This loss-of-function model is generated in the Homo sapiens HAP1 fibroblast-like cell line, providing a powerful tool for studying HABP4-dependent cellular processes. The polyclonal format offers a heterogeneous knockout cell pool, suitable for applications where pooled genotypic diversity is advantageous. The product is designed for use in functional genomics, cancer research, and molecular biology investigations.
HAP1 cells are a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia line. Their near-haploid karyotype reduces genetic redundancy, simplifying gene-editing outcomes and facilitating unambiguous interpretation of knockout phenotypes. These fibroblast-like cells are widely employed in genetic screening and functional genomic studies due to their ease of manipulation and reproducible growth characteristics. The HAP1 background thus provides an ideal host for CRISPR-mediated disruption of HABP4, enabling precise analysis of gene function without interference from extra alleles.
HABP4 encodes an intracellular hyaluronan-binding protein that functions as a modulator of mRNA splicing through its interaction with the serine/arginine-rich splicing factor SRSF1. It also associates with the tumor suppressor TP53 and is implicated in p53-mediated stress responses, integrating signals from DNA damage and the PI3K/AKT pathway. HABP4??s downstream effects influence splicing regulators and cell cycle genes, thereby coordinating post-transcriptional gene expression with cell proliferation control. The mechanistic interplay between HABP4 and components such as DYNLL1, CDKN1A, PIK3CA, AKT1, and TGFB1 highlights its role in multiple signaling axes, including p53, PI3K/AKT, and TGF-beta pathways. Disruption of HABP4 in this model therefore perturbs splicing fidelity and may alter proliferation and apoptotic responses.
In the HAP1 cellular context, HABP4 knockout provides a clean system to dissect its tumor-suppressive functions. The near-haploid nature minimizes compensatory effects from homologous genes, allowing researchers to link HABP4 loss directly to phenotypic changes such as deregulated splicing and aberrant cell growth. This model is particularly relevant for studying cancers where HABP4 dysregulation has been observed, including glioblastoma, hepatocellular carcinoma, and leukemia. By evaluating HABP4??s impact on p53 target genes and PI3K/AKT signaling within a simplified genomic background, investigators can gain insights into the molecular mechanisms underlying tumorigenesis and identify potential therapeutic vulnerabilities.
Researchers can employ this polyclonal knockout cell population in a diverse array of experiments. Functional genomics studies may utilize RNA-seq to assess transcriptome-wide splicing changes, while RT-qPCR and western blotting validate alterations in HABP4, SRSF1, or TP53 expression. Proliferation and apoptosis assays quantify the effects of HABP4 loss on cell fitness, and splicing reporter assays directly monitor splicing efficiency. The polyclonal format is also suited for drug target identification screens, as the mixed population can reveal differential responses to candidate compounds. This product serves as a robust platform for advancing understanding of HABP4 biology in cancer and splicing research. For additional information, please contact Ascent Research.
